Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)
October 2012 (From -To) From 03-08-March2011-07 September2012
REPORT TYPE

Final
DATES COVERED
TITLE AND SUBTITLE
Identification of Small Molecules Targeting the Posttranscriptional Control of ERG Expression
5a. CONTRACT NUMBER
W81XWH-11-1-0015
5b. GRANT NUMBER-W81XWH-11-1-0015 5c. PROGRAM ELEMENT NUMBER
AUTHOR(S)
Yijun Zhu 5d. PROJECT NUMBER 5e. TASK NUMBER Cqi451@northwestern.edu 5f. WORK UNIT NUMBER
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER
Northwestern University
Evanston, IL 60208
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materials Command
Fort Detrick, Maryland 21702-
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited.
SUPPLEMENTARY NOTES
ABSTRACT
TMPRSS2-ERG translocation is involve d in about 60% of prostate canc ers. The translocation leads to overexpression of ERG which prom otes cell proliferati on and abrogates prostate epithelial differentiation. Suppression of ERG expression represen ts a major way to treat prostate can cers. However, there are no effective means to inhibit ERG expression. Although siRNA can deplet e ERG expression, the big challenge is to deliver siRNA into prostate cancer cells. The mRNA stability, translation efficiency and protein stability of ERG are under strict control to maintain the ERG protein level. Here we report the establishment of a cell line which can be used to identify small molecules which inhibit ERG expression by targeting its post-transcriptional process. Using this cell line, we performed high-throughput screening and identif ied Gambogic acid which suppr esses ERG expression in ERG-overexpressing prostate cancer cells.
SUBJECT TERMS
Prostate carcinoma; ERG; small molecules, post-transcriptional.
SECURITY CLASSIFICATION OF:
17 We at fir st generated a vector whic h expresses a trans cript composed of c oding region for luci ferase and ERG fusi on protein and the 3'UTR of ERG ( Fig. 1) with pCDNA3.1. The inclusion of the reporter l uciferase cDNA into ERG cDNA allowed the identification of small molecules which affect ERG mRNA stability and translation efficiency. By using th e in-frame fusion of lucifera se with ERG cDNA, chem icals affecting ERG pr otein stability can also be identif ied. To establish a cell line expressing lucife rase-ERG fusion protein, the vector along pRL-CMV-Rluc expressing Renilla luciferase gene was transf ected into LNCaP cells. The pRL-CMV-Rluc served as an intern al control. The cells were treated with G418. I ndividual clones were isolated, expanded, and examined for the e xpression of t wo different luciferases. A clone expressing both Firefly luciferase and Renilla luciferase was selected for further studies.
Task 2. Perform high throughput screening for small molecules (months 5-9). 1. high throughput screeni Task 2. Perform high throughput screening for small molecules.
The screening was performed in our university core facility. Ten thousand reporter cells were seeded per well in 384 wellplates and were treated with the individual chemical at 10 μM for 24 h. The dual luciferase activities were measured. The ratio of Firefly to Renilla lu ciferase activity was calculat ed. The ratio value decreased to 40% of the value fr om the control cells were considered as a hit and selected for further analysis. From a total of 5 hits, we identified Gambogic acid which consistently suppressed Firefly lu ciferase activity compared with Renilla luciferase activity (Fig. 2a) . We confirmed that Gambogic acid decreased the protein level of ERG-Luciferase fusion protein (Fig. 2b) .
Task 3. Test if the identified molecules can inhibit the proliferation of prostate cancers by inhibiting ERG protein expression. VCaP cells which carry TMPRSS2-ERG translocation were treated with Gamb ogic acid or control vehicle for 48h. Rea l time RT-PCR for ERG revealed that ERG mRNA was not changed (Fig. 3a) , indicating that the compound does not affect the ERG mRNA stability. However, Western blot revealed that ERG prot ein was reduced by the treatment (Fig. 3b) . Pulse-chase experiment revealed that ERG protein is less stable when treated with Gambogic acid (Fig. 3c) , indicating that the compound acts through down-regulating the protein stability. 
KEY RESEARCH ACCOMPLISHMENTS
* We report the establishm ent of a cell line which can be used to identify small mole cules inhibiting ERG expression.
* We performed high-throughput screening and identified Gambogic acid which suppresses ERG-Luc expression.
* We found that Gambogic acid inhibits the expression of ERG in ERG-overexpressing prostate cancer cells.
.
CONCLUSIONS
We report t he establishment of a cell line whi ch can be used to iden tify small molecu les which i nhibit ERG expression. Using this cell line, we per formed high-throughput screening and identified Gambogic acid which s uppresses ERG-Luc fusion protein expression. We found that Gambogic acid can s uppress ERG expression in ERG overexpressing prostate cancer cells.
